Kidney transplantation is the preferred treatment of choice for almost all categories of patients with end-stage-renal disease (ESRD) including those with hypertension, glomerulonephritis, diabetes mellitus and genetic causes as polycystic renal disease. Transplanted patients will live approximately 10-15 years longer than patients that remain on dialysis. In light of the increased donor shortage and the increasing waiting time, the number of kidney transplants from living donors enormously increased during the last decade. Complete matching for major Human Leucocyte Antigen (HLA) molecules between donor and recipients is preferable, but due to the high degree of polymorphism of HLA, only some recipients with a suitable living-related sibling donor receive a fully HLA-identical donor kidney.

, , ,
The Dutch Kidney Foundation (Nederlandse Nierstichting) The Dutch Transplantation Society (Nederlandse Transplantatie Vereniging), Stichting Medisch Laboratorium Noord, U-CyTech B.V., Roche Diagnostics Nederland B.V., Genzyme Europe B.V., Astellas Pharma B.V., Novartis Pharma B.V, Roche Nederland B.V.
W. Weimar (Willem)
Erasmus University Rotterdam
Erasmus MC: University Medical Center Rotterdam

Gerrits, J. (2010, January 8). Donor-Reactive T-cell Responses after HLA-Identical Living-Related Kidney Transplantation. Retrieved from